Provided by Tiger Fintech (Singapore) Pte. Ltd.

Contineum Therapeutics, INC.

6.67
-0.4700-6.58%
Post-market: 6.670.00000.00%16:05 EDT
Volume:61.60K
Turnover:419.22K
Market Cap:171.94M
PE:-3.11
High:7.28
Open:7.18
Low:6.42
Close:7.14
Loading ...

Contineum Therapeutics Completes Enrollment in Phase 2 Pipe-307 Vista Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (Rrms)

THOMSON REUTERS
·
09 Jan

BRIEF-Rapt Therapeutics Names Lori Lyons-Williams Chair Of The Board

Reuters
·
06 Jan

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

THOMSON REUTERS
·
06 Jan

RAPT Therapeutics Inc - William Rieflin Steps Down as Chair, Remains Consultant

THOMSON REUTERS
·
06 Jan

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

GlobeNewswire
·
06 Jan

Top Premarket Decliners

MT Newswires Live
·
27 Dec 2024

Contineum Starts Patient Dosing in Positron Emission Tomography Trial

MT Newswires Live
·
17 Dec 2024

BRIEF-Contineum Therapeutics Initiates Patient Dosing In Phase 1B Positron Emission Tomography (Pet) Trial Of Pipe-791

Reuters
·
17 Dec 2024

Contineum initiates patient dosing in Phase 1B PET trial

TIPRANKS
·
17 Dec 2024

Contineum Therapeutics Initiates Patient Dosing in Phase 1B Positron Emission Tomography (Pet) Trial of Pipe-791

THOMSON REUTERS
·
17 Dec 2024

Contineum Therapeutics Inc - Doses First Cohort in Pipe-791 Phase 1B Trial

THOMSON REUTERS
·
17 Dec 2024

Contineum Therapeutics Inc - Anticipates Topline Data From Pipe-791 Trial in Q2 2025

THOMSON REUTERS
·
17 Dec 2024

Contineum Therapeutics Inc - Topline Data Readout Expected in Q2 2025

THOMSON REUTERS
·
17 Dec 2024

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Business Wire
·
17 Dec 2024

Contineum Therapeutics: Q3 2024 Financial Overview

TIPRANKS
·
26 Nov 2024

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Business Wire
·
25 Nov 2024